Linker-specific monoclonal antibodies present a simple and reliable detection method for scFv-based CARNK cells
Chimeric antigen receptor (CAR) T cell therapies have demonstrated significant successes in treating cancer.Currently, there are six approved CAR T cell products available on the market that target different malignancies of the B cell lineage.However, to overcome the limitations of CAR T cell therapies, other immune cells are being investigated for